G/MA/QR/N/GBR/1/Add. 2 
5 de agosto  de 2022 
(22-5846) Página: 1/6 
Comité de Acceso a los Mercados  Original:  inglés  
 
  
NOTIFICACIÓN DE CONFORMIDAD CON LA DECISIÓN SOBRE  
EL PROCEDIMIENTO DE NOTIFICACIÓN DE RESTRICCIONES  
CUANTITATIVAS (G/L/59/REV.1)  
REINO UNIDO 
Addendum  
La siguiente comunicación, de fecha 3 de agosto  de 2022 , se distribuye a petición de la delegación 
del Reino Unido.  
A. Miembro notificante : Reino Unido  
B. Fecha de la notificación : 3 de agosto  de 2022  
C. Primera  notificación:  
 Sí 
 No, la última notificación se presentó con la signatura (signatura del documento) : 
G/L/59/Rev.1  
D. Tipo de notificación:  
 1. Completa (es decir, notificación de todas las restricciones cuantitativas en vigor)  
 2. Cambios de una notificación presentada anteriormente con la signatura 
G/MA/QR/N/GBR/1 consistentes en lo siguiente:  
 2.1 Establecimiento de nuevas restricciones, enumeradas en la sección 1.  
 2.2 Eliminación de restricciones, como se describe e n la casilla G infra.  
 2.3 Modificación de una restricción notificada anteriormente, como se indica en l a 
sección 1.  
 3. Notificación inversa de restricciones mantenidas por (Miembro):  
E. La notificación proporciona información sobre el siguiente período bienal 
(por ejemplo, 2012 -2014) : 2020-2022 y se refiere a restricciones en vigor al  
24 de junio de 202 2 
F. La presente notificación contiene información* relativa a:  
 Sección 1 : Lista de restricciones cuantitativas actualmente en vigor.  
 Sección 2 : Referencia a otras notificaciones presentadas a la OMC que contengan 
información sobre restricciones cuantitativas actualmente en vigor e 
información adicional.  
 
* En inglés solamente.  G/MA/QR/N/GBR/1/Add. 2 
- 2 - 
  G. Observaciones de carácter general, con inclusión de una descripción de la 
eliminación de restricciones notificada en el apartado 2.2 de la casilla D y la fecha 
en que esas restricciones dejaron de estar en vigor.  
1. El presente addendum  modifica y sustituye a la notificación de la restricción cuantitativa 
nº 21 (G/MA/QR/N/GBR/1 ). En esta notificación se actualiza la lista de códigos de productos 
aplicables a los medicamentos abarcados y se facilita más información sobre la  designación 
de los productos . 
2. El Re ino Unido notifica la reducción neta de 30 medicamentos de la lista de medicamentos 
necesarios para apoyar el tratamiento de pacientes del Reino Unido en un momento en que 
la COVID -19 sigue teniendo un efecto real tanto en la demanda como en la oferta de 
medicamentos, cuya exportación está sujeta a restricciones en determinadas circunstancias 
limitadas cuando esos medicamentos ya están en la cadena de suministro del Reino Unido 
y destinados a pacientes del Reino Unido.  
3. Se trata de medidas temporales, ado ptadas con el fin de aliviar una escasez crítica de 
medicamentos necesarios para proteger la salud humana. Las medidas se examinan 
periódicamente y solo se aplican cuando la necesidad crítica no puede satisfacerse mediante 
medidas alternativas. El 15 de diciembre  de 2021 se retiraron de la lista 47 medicamentos. 
Al 24 de junio de 202 2, se habían retirado de la lista otros 32 medicamentos. Se ha n 
añadido  2 medicamento s a la lista.  
4. La notificación G/MA/QR/N/GBR /1 del Reino Unido incluía detalles relativos a Irlanda del 
Norte. La presente notificación no modifica dichos detalles, que siguen aplicándose.  
   
  G/MA/QR/N/GBR/1/Add. 2 
- 3 - 
 
Section 1: List of quantitative restrictions that are currently in force  
 
QR
No. General 
description of the 
restriction  Type of 
restriction  
 Tariff line 
code(s) 
affected, 
based on  
HS (2022)  Detailed Product 
Description  WTO Justification 
and Grounds for 
Restriction, e.g., 
Other International 
Commitments  National legal basis 
and entry into force   
 Administration, 
modification of 
previously notified 
measures, and 
other comments  
1 2 3 4 5 6 7 
1 Measures to 
regulate exports of 
certain 
medicaments.  CP-X Medicines fall 
under the 
following 
commodity 
codes:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3002.41.90  1. Heading 3002 - 
Classification  
Human blood; animal 
blood prepared for 
therapeutic, 
prophylactic or 
diagnostic uses; 
antisera, other blood 
fractions and 
immunological 
products, whether or 
not modified or 
obtained by means of 
biotechnological 
processes; vaccines, 
toxins, cultures of 
micro -organisms 
(excluding yeasts) and 
similar products; cell 
cultures, w hether or 
not modified  
 
 
 
Product Description 
per Commodity Code 
under Heading 3002  
 
Vaccines, toxins, 
cultures of micro -
organisms (excluding 
yeasts) and similar 
products, Other  Article XX(b) GATT  
Protection of human, 
animal or plant life or 
health.  
 Regulation 43(2) of the 
Human Medicines 
Regulations 2012 
requiring wholesale 
dealers to ensure 
continued supply of 
medicinal products so 
that the needs of 
patients in the UK are 
met. Further details can 
be found through: 
https://www.legislation.
gov.uk/uksi/2012/1916/
contents/made  
 
The date restrictions 
came into effect varies 
by medicine; this is 
specified for each 
medicine on the list, 
updated on 
24 June 2022 and 
available on go v.uk at  
 
https://assets.publishing
.service.gov.uk/governm
ent/uploads/system/uplo
ads/attachment_data/fil
e/1042790/restricted -
medicines -list-
december -2021-
v3.csv/preview   
 
 The list of medicines 
is maintained by the 
Department of 
Health and Social 
Care.  
 
These measures are 
reviewed regularly.  
A full change log of 
previous measures, 
from October 2019, 
can be found here:  
https://www.gov.uk/
government/publicati
ons/medicines -that-
cannot -be-parallel -
exporte d-from-the-
uk  
 
Medicines included 
on this list meet the 
following conditions:  
• The medicine is 
required to meet 
the needs of UK 
patients  
• The medicine is 
currently in 
shortage or risk 
of being in 
shortage  
• The export of 
the medicine 
would contribute 
to or exacerbate 
a shortage, or 
risk of shortage,   
  G/MA/QR/N/GBR/1/Add. 2 
- 4 - 
 
QR
No. General 
description of the 
restriction  Type of 
restriction  
 Tariff line 
code(s) 
affected, 
based on  
HS (2022)  Detailed Product 
Description  WTO Justification 
and Grounds for 
Restriction, e.g., 
Other International 
Commitments  National legal basis 
and entry into force   
 Administration, 
modification of 
previously notified 
measures, and 
other comments  
1 2 3 4 5 6 7 
of that medicine 
in the UK  
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3004.20.00  
 
 
 
 
 
 
3004.31.00  
 
 
 
3004.32.00  
 
 
 
 
 
3004.39.00  
 
 
 2. Heading 3004 - 
Classification  
Medicaments 
consisting of mixed or 
unmixed products for 
therapeutic or 
prophylactic uses, put 
up in measured doses 
(including those in the 
form of transdermal 
administration 
systems) or in forms 
or packings for retail 
sale 
 
Product Description 
per Commodity Code 
under Heading 3004  
Other, containing 
antibiotics  
 
Other, containing 
hormones or other 
products of heading 
2937 
Containing insulin  
 
 
 
Contain ing 
corticosteroid 
hormones, their 
derivatives or 
structural analogues  
 
Other  
  
  Medicines on this list 
which have been 
produced to fulfil 
contracts overseas 
are not subject to 
restriction. As such, 
restrictions only 
apply to wholesaler 
dealer license 
holders that are not 
the market 
authorisation holder 
for a medicine 
intended for export. 
The measures are 
designed to ensure 
wholesalers fulfil 
their legal obligations 
to maintain supply to 
UK patients.  
 
These restrictions are 
only applied and 
maintained where  
alternative measures 
are not considered 
sufficient on their 
own to ensure that 
UK supply meets 
demand.  
A number of 
exem ptions apply to 
medicines in scope of 
these restrictions. 
For example, exports 
destined for 
international   
  G/MA/QR/N/GBR/1/Add. 2 
- 5 - 
 
QR
No. General 
description of the 
restriction  Type of 
restriction  
 Tariff line 
code(s) 
affected, 
based on  
HS (2022)  Detailed Product 
Description  WTO Justification 
and Grounds for 
Restriction, e.g., 
Other International 
Commitments  National legal basis 
and entry into force   
 Administration, 
modification of 
previously notified 
measures, and 
other comments  
1 2 3 4 5 6 7 
3004.49.00  
 
 
 
 
3004.90.00   
Other, containing 
alkaloids or derivatives 
thereof, Other  
 
 
Other  
Further detail of these 
medicines can be 
found at  
https://www.gov.uk/g
overnment/publication
s/medicines -that-
cannot -be-parallel -
exported -from-the-uk 
 
These restrictions 
apply in certain 
circumstances to 
exports of specified 
medicines which are 
placed on the UK 
market for UK patients 
and needed to protect 
human health, 
including to treat 
Covid -19, inter alia. 
 
 humanitarian 
organisations such as 
COVAX are not 
covered. A full list of 
exemptions can be 
found at 
https://www.gov.uk/
government/publicati
ons/medicines -that-
cannot -be-parallel -
exported -from-the-
uk 
 
Requests for 
exemptions are 
considered on a 
case-by-case basis. 
These can be 
submitted by a 
foreign government  
or government 
agency, or a 
wholesaler on their 
behalf at 
restrictedmedicines@
dhsc.gov.uk    
 
Further information 
on these measures is 
available here:  
https://www.gov.uk/
guidance/parallel -
export -and-hoarding -
of-restricted -
medicines    
  G/MA/QR/N/GBR/1/Add. 2 
- 6 - 
 
QR
No. General 
description of the 
restriction  Type of 
restriction  
 Tariff line 
code(s) 
affected, 
based on  
HS (2022)  Detailed Product 
Description  WTO Justification 
and Grounds for 
Restriction, e.g., 
Other International 
Commitments  National legal basis 
and entry into force   
 Administration, 
modification of 
previously notified 
measures, and 
other comments  
1 2 3 4 5 6 7 
       It is the 
responsibility of the 
wholesaler to ensure 
any exports are 
made or withheld in 
compliance with 
these restrictions. 
Failure to comply 
with these 
restrictions may lead 
to regulatory action 
by the Medicines and 
Healthcare products 
Regulatory Authority 
(MHRA) against the 
wholesale dealer's 
licence.  
There are no 
additional steps or 
declarations required 
from a customs 
perspective.  
 
__________